APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tuberculosis Vaccine Treatment

Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.

Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.

Selected research

Market Outlook & Growth Opportunities

Global Tuberculosis Vaccine Treatment Market Outlook and Growth Opportunities 2026

28 December 2025193 pages

Choose your research edition.

Industry ResearchTuberculosis Vaccine Treatment Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Tuberculosis Vaccine Treatment Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Tuberculosis Vaccine Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tuberculosis Vaccine Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Tuberculosis Vaccine Treatment Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.

Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.

In the last several years, global market of Tuberculosis Vaccine Treatment developed smoothly, with an average growth rate of 0.73%.

Read the full market overview

The classification of Tuberculosis Vaccine Treatment includes Immune Vaccine and Therapy Vaccine, and the proportion of Immune Vaccine in 2019 is about 99.66%.

Tuberculosis Vaccine Treatment is widely sold through Self-Procurement, UNICEF and Other. The most proportion of Tuberculosis Vaccine Treatment is sold through Self-Procurement, and the proportion in 2019 is 62.14%.

Asia-Pacific is the largest consumption place, with a consumption market share nearly 45% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of 35.66%.

Market competition is intense. Merck, Japan BCG Lab, Serum Institute of India are the leaders of the industry, they occupy the 60% of the market.

This report provides an overview of the global Tuberculosis Vaccine Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tuberculosis Vaccine Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tuberculosis Vaccine Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tuberculosis Vaccine Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Tuberculosis Vaccine Treatment Segment by Company

Merck

Japan BCG Lab

Serum Institute of India

AJ Vaccines

BioFarma

GreenSignal Bio Pharma

China National Biotec

Biomed Lublin

Taj Pharmaceuticals

Ataulpho de Paiva

IVAC

Queen Saovabha Mem. Inst

Microgen

Tuberculosis Vaccine Treatment Segment by Type

Immune Vaccine

Therapy Vaccine

Tuberculosis Vaccine Treatment Segment by Application

Self-Procurement

UNICEF

Other

Tuberculosis Vaccine Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Tuberculosis Vaccine Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Tuberculosis Vaccine Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tuberculosis Vaccine Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Tuberculosis Vaccine Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Vaccine Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Vaccine Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Vaccine Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tuberculosis Vaccine Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tuberculosis Vaccine Treatment industry.

Chapter 3: Detailed analysis of Tuberculosis Vaccine Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Tuberculosis Vaccine Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Tuberculosis Vaccine Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tuberculosis Vaccine Treatment Industry Trends Table 2. Tuberculosis Vaccine Treatment Industry Drivers Table 3. Tuberculosis Vaccine Treatment Industry Opportunities and Challenges Table 4. Tuberculosis Vaccine Treatment Industry Restraints Table 5. Global Tuberculosis Vaccine Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tuberculosis Vaccine Treatment Revenue Share by Company (2021-2026) Table 7. Global Tuberculosis Vaccine Treatment Sales Volume by Company (K Dose) & (2021-2026) Table 8. Global Tuberculosis Vaccine Treatment Sales Volume Share by Company (2021-2026) Table 9. Global Tuberculosis Vaccine Treatment Average Price (USD/K Dose) of Company (2021-2026) Table 10. Global Tuberculosis Vaccine Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global Tuberculosis Vaccine Treatment Key Company Manufacturing Base & Headquarters Table 12. Global Tuberculosis Vaccine Treatment Company, Product Type & Application Table 13. Global Tuberculosis Vaccine Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Tuberculosis Vaccine Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Immune Vaccine Table 18. Significant Companies of Therapy Vaccine Table 19. Global Tuberculosis Vaccine Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (K Dose) Table 20. Global Tuberculosis Vaccine Treatment Sales Volume by Type (2021-2026) & (K Dose) Table 21. Global Tuberculosis Vaccine Treatment Sales Volume by Type (2027-2032) & (K Dose) Table 22. Global Tuberculosis Vaccine Treatment Sales Volume Share by Type (2021-2026) Table 23. Global Tuberculosis Vaccine Treatment Sales Volume Share by Type (2027-2032) Table 24. Global Tuberculosis Vaccine Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Tuberculosis Vaccine Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Tuberculosis Vaccine Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Tuberculosis Vaccine Treatment Sales Value Share by Type (2021-2026) Table 28. Global Tuberculosis Vaccine Treatment Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Self-Procurement Table 30. Significant Companies of UNICEF Table 31. Significant Companies of Other Table 32. Global Tuberculosis Vaccine Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (K Dose) Table 33. Global Tuberculosis Vaccine Treatment Sales Volume by Application (2021-2026) & (K Dose) Table 34. Global Tuberculosis Vaccine Treatment Sales Volume by Application (2027-2032) & (K Dose) Table 35. Global Tuberculosis Vaccine Treatment Sales Volume Share by Application (2021-2026) Table 36. Global Tuberculosis Vaccine Treatment Sales Volume Share by Application (2027-2032) Table 37. Global Tuberculosis Vaccine Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Tuberculosis Vaccine Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Tuberculosis Vaccine Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Tuberculosis Vaccine Treatment Sales Value Share by Application (2021-2026) Table 41. Global Tuberculosis Vaccine Treatment Sales Value Share by Application (2027-2032) Table 42. Global Tuberculosis Vaccine Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Dose) Table 43. Global Tuberculosis Vaccine Treatment Sales by Region (2021-2026) & (K Dose) Table 44. Global Tuberculosis Vaccine Treatment Sales Market Share by Region (2021-2026) Table 45. Global Tuberculosis Vaccine Treatment Sales by Region (2027-2032) & (K Dose) Table 46. Global Tuberculosis Vaccine Treatment Sales Market Share by Region (2027-2032) Table 47. Global Tuberculosis Vaccine Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Tuberculosis Vaccine Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Tuberculosis Vaccine Treatment Sales Value Share by Region (2021-2026) Table 50. Global Tuberculosis Vaccine Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Tuberculosis Vaccine Treatment Sales Value Share by Region (2027-2032) Table 52. Global Tuberculosis Vaccine Treatment Market Average Price (USD/K Dose) by Region (2021-2026) Table 53. Global Tuberculosis Vaccine Treatment Market Average Price (USD/K Dose) by Region (2027-2032) Table 54. Global Tuberculosis Vaccine Treatment Sales by Country: 2021 VS 2025 VS 2032 (K Dose) Table 55. Global Tuberculosis Vaccine Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Tuberculosis Vaccine Treatment Sales by Country (2021-2026) & (K Dose) Table 57. Global Tuberculosis Vaccine Treatment Sales Market Share by Country (2021-2026) Table 58. Global Tuberculosis Vaccine Treatment Sales by Country (2027-2032) & (K Dose) Table 59. Global Tuberculosis Vaccine Treatment Sales Market Share by Country (2027-2032) Table 60. Global Tuberculosis Vaccine Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Tuberculosis Vaccine Treatment Sales Value Market Share by Country (2021-2026) Table 62. Global Tuberculosis Vaccine Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Tuberculosis Vaccine Treatment Sales Value Market Share by Country (2027-2032) Table 64. Merck Company Information Table 65. Merck Business Overview Table 66. Merck Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 67. Merck Tuberculosis Vaccine Treatment Product Portfolio Table 68. Merck Recent Development Table 69. Japan BCG Lab Company Information Table 70. Japan BCG Lab Business Overview Table 71. Japan BCG Lab Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 72. Japan BCG Lab Tuberculosis Vaccine Treatment Product Portfolio Table 73. Japan BCG Lab Recent Development Table 74. Serum Institute of India Company Information Table 75. Serum Institute of India Business Overview Table 76. Serum Institute of India Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 77. Serum Institute of India Tuberculosis Vaccine Treatment Product Portfolio Table 78. Serum Institute of India Recent Development Table 79. AJ Vaccines Company Information Table 80. AJ Vaccines Business Overview Table 81. AJ Vaccines Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 82. AJ Vaccines Tuberculosis Vaccine Treatment Product Portfolio Table 83. AJ Vaccines Recent Development Table 84. BioFarma Company Information Table 85. BioFarma Business Overview Table 86. BioFarma Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 87. BioFarma Tuberculosis Vaccine Treatment Product Portfolio Table 88. BioFarma Recent Development Table 89. GreenSignal Bio Pharma Company Information Table 90. GreenSignal Bio Pharma Business Overview Table 91. GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 92. GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Product Portfolio Table 93. GreenSignal Bio Pharma Recent Development Table 94. China National Biotec Company Information Table 95. China National Biotec Business Overview Table 96. China National Biotec Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 97. China National Biotec Tuberculosis Vaccine Treatment Product Portfolio Table 98. China National Biotec Recent Development Table 99. Biomed Lublin Company Information Table 100. Biomed Lublin Business Overview Table 101. Biomed Lublin Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 102. Biomed Lublin Tuberculosis Vaccine Treatment Product Portfolio Table 103. Biomed Lublin Recent Development Table 104. Taj Pharmaceuticals Company Information Table 105. Taj Pharmaceuticals Business Overview Table 106. Taj Pharmaceuticals Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 107. Taj Pharmaceuticals Tuberculosis Vaccine Treatment Product Portfolio Table 108. Taj Pharmaceuticals Recent Development Table 109. Ataulpho de Paiva Company Information Table 110. Ataulpho de Paiva Business Overview Table 111. Ataulpho de Paiva Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 112. Ataulpho de Paiva Tuberculosis Vaccine Treatment Product Portfolio Table 113. Ataulpho de Paiva Recent Development Table 114. IVAC Company Information Table 115. IVAC Business Overview Table 116. IVAC Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 117. IVAC Tuberculosis Vaccine Treatment Product Portfolio Table 118. IVAC Recent Development Table 119. Queen Saovabha Mem. Inst Company Information Table 120. Queen Saovabha Mem. Inst Business Overview Table 121. Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 122. Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Product Portfolio Table 123. Queen Saovabha Mem. Inst Recent Development Table 124. Microgen Company Information Table 125. Microgen Business Overview Table 126. Microgen Tuberculosis Vaccine Treatment Sales (K Dose), Value (US$ Million), Price (USD/K Dose) and Gross Margin (2021-2026) Table 127. Microgen Tuberculosis Vaccine Treatment Product Portfolio Table 128. Microgen Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Tuberculosis Vaccine Treatment Distributors List Table 132. Tuberculosis Vaccine Treatment Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Tuberculosis Vaccine Treatment Product Image Figure 2. Global Tuberculosis Vaccine Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tuberculosis Vaccine Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global Tuberculosis Vaccine Treatment Sales (2021-2032) & (K Dose) Figure 5. Global Tuberculosis Vaccine Treatment Sales Average Price (USD/K Dose) & (2021-2032) Figure 6. Global Tuberculosis Vaccine Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Immune Vaccine Image Figure 10. Therapy Vaccine Image Figure 11. Global Tuberculosis Vaccine Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (K Dose) Figure 12. Global Tuberculosis Vaccine Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Tuberculosis Vaccine Treatment Sales Volume Share by Type (2021-2032) Figure 14. Global Tuberculosis Vaccine Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Tuberculosis Vaccine Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Tuberculosis Vaccine Treatment Sales Value Share by Type (2021-2032) Figure 17. Self-Procurement Image Figure 18. UNICEF Image Figure 19. Other Image Figure 20. Global Tuberculosis Vaccine Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (K Dose) Figure 21. Global Tuberculosis Vaccine Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Tuberculosis Vaccine Treatment Sales Volume Share by Application (2021-2032) Figure 23. Global Tuberculosis Vaccine Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Tuberculosis Vaccine Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Tuberculosis Vaccine Treatment Sales Value Share by Application (2021-2032) Figure 26. Global Tuberculosis Vaccine Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Dose) Figure 27. Global Tuberculosis Vaccine Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Tuberculosis Vaccine Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Tuberculosis Vaccine Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Tuberculosis Vaccine Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. North America Tuberculosis Vaccine Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Tuberculosis Vaccine Treatment Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Tuberculosis Vaccine Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Tuberculosis Vaccine Treatment Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Tuberculosis Vaccine Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Tuberculosis Vaccine Treatment Sales Value (2021-2032) & (US$ Million) Figure 37. South America Tuberculosis Vaccine Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Tuberculosis Vaccine Treatment Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Tuberculosis Vaccine Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Tuberculosis Vaccine Treatment Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Tuberculosis Vaccine Treatment Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Vaccine
  • Therapy Vaccine
Applications
  • Self-Procurement
  • UNICEF
  • Other
Companies covered
  • Merck
  • Japan BCG Lab
  • Serum Institute of India
  • AJ Vaccines
  • BioFarma
  • GreenSignal Bio Pharma
  • China National Biotec
  • Biomed Lublin
  • Taj Pharmaceuticals
  • Ataulpho de Paiva
  • IVAC
  • Queen Saovabha Mem. Inst
  • Microgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Tuberculosis Vaccine Treatment Sales Value (2021-2032)
  4. 1.2.2 Global Tuberculosis Vaccine Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global Tuberculosis Vaccine Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Tuberculosis Vaccine Treatment Market Dynamics
  1. 2.1 Tuberculosis Vaccine Treatment Industry Trends
  2. 2.2 Tuberculosis Vaccine Treatment Industry Drivers
  3. 2.3 Tuberculosis Vaccine Treatment Industry Opportunities and Challenges
  4. 2.4 Tuberculosis Vaccine Treatment Industry Restraints
3 Tuberculosis Vaccine Treatment Market by Company
  1. 3.1 Global Tuberculosis Vaccine Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Tuberculosis Vaccine Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Tuberculosis Vaccine Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global Tuberculosis Vaccine Treatment Average Price by Company (2021-2026)
  5. 3.5 Global Tuberculosis Vaccine Treatment Company Ranking (2024-2026)
  6. 3.6 Global Tuberculosis Vaccine Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global Tuberculosis Vaccine Treatment Company Product Type and Application
  8. 3.8 Global Tuberculosis Vaccine Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Tuberculosis Vaccine Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Tuberculosis Vaccine Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Tuberculosis Vaccine Treatment Market by Type
  1. 4.1 Tuberculosis Vaccine Treatment Type Introduction
  2. 4.1.1 Immune Vaccine
  3. 4.1.2 Therapy Vaccine
  4. 4.2 Global Tuberculosis Vaccine Treatment Sales Volume by Type
  5. 4.2.1 Global Tuberculosis Vaccine Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Tuberculosis Vaccine Treatment Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Tuberculosis Vaccine Treatment Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Tuberculosis Vaccine Treatment Sales Value by Type
  9. 4.3.1 Global Tuberculosis Vaccine Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Tuberculosis Vaccine Treatment Sales Value by Type (2021-2032)
  11. 4.3.3 Global Tuberculosis Vaccine Treatment Sales Value Share by Type (2021-2032)
5 Tuberculosis Vaccine Treatment Market by Application
  1. 5.1 Tuberculosis Vaccine Treatment Application Introduction
  2. 5.1.1 Self-Procurement
  3. 5.1.2 UNICEF
  4. 5.1.3 Other
  5. 5.2 Global Tuberculosis Vaccine Treatment Sales Volume by Application
  6. 5.2.1 Global Tuberculosis Vaccine Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Tuberculosis Vaccine Treatment Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Tuberculosis Vaccine Treatment Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Tuberculosis Vaccine Treatment Sales Value by Application
  10. 5.3.1 Global Tuberculosis Vaccine Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Tuberculosis Vaccine Treatment Sales Value by Application (2021-2032)
  12. 5.3.3 Global Tuberculosis Vaccine Treatment Sales Value Share by Application (2021-2032)
6 Tuberculosis Vaccine Treatment Regional Sales and Value Analysis
  1. 6.1 Global Tuberculosis Vaccine Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tuberculosis Vaccine Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Tuberculosis Vaccine Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global Tuberculosis Vaccine Treatment Sales by Region (2027-2032)
  5. 6.3 Global Tuberculosis Vaccine Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Tuberculosis Vaccine Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global Tuberculosis Vaccine Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global Tuberculosis Vaccine Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global Tuberculosis Vaccine Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Tuberculosis Vaccine Treatment Sales Value (2021-2032)
  12. 6.6.2 North America Tuberculosis Vaccine Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Tuberculosis Vaccine Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe Tuberculosis Vaccine Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Tuberculosis Vaccine Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Tuberculosis Vaccine Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Tuberculosis Vaccine Treatment Sales Value (2021-2032)
  21. 6.9.2 South America Tuberculosis Vaccine Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Tuberculosis Vaccine Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Tuberculosis Vaccine Treatment Sales Value Share by Country, 2025 VS 2032
7 Tuberculosis Vaccine Treatment Country-level Sales and Value Analysis
  1. 7.1 Global Tuberculosis Vaccine Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tuberculosis Vaccine Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Tuberculosis Vaccine Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global Tuberculosis Vaccine Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global Tuberculosis Vaccine Treatment Sales by Country (2027-2032)
  6. 7.4 Global Tuberculosis Vaccine Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global Tuberculosis Vaccine Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global Tuberculosis Vaccine Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Tuberculosis Vaccine Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Tuberculosis Vaccine Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Tuberculosis Vaccine Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Tuberculosis Vaccine Treatment Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Japan BCG Lab
  8. 8.2.1 Japan BCG Lab Company Information
  9. 8.2.2 Japan BCG Lab Business Overview
  10. 8.2.3 Japan BCG Lab Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Japan BCG Lab Tuberculosis Vaccine Treatment Product Portfolio
  12. 8.2.5 Japan BCG Lab Recent Developments
  13. 8.3 Serum Institute of India
  14. 8.3.1 Serum Institute of India Company Information
  15. 8.3.2 Serum Institute of India Business Overview
  16. 8.3.3 Serum Institute of India Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Serum Institute of India Tuberculosis Vaccine Treatment Product Portfolio
  18. 8.3.5 Serum Institute of India Recent Developments
  19. 8.4 AJ Vaccines
  20. 8.4.1 AJ Vaccines Company Information
  21. 8.4.2 AJ Vaccines Business Overview
  22. 8.4.3 AJ Vaccines Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AJ Vaccines Tuberculosis Vaccine Treatment Product Portfolio
  24. 8.4.5 AJ Vaccines Recent Developments
  25. 8.5 BioFarma
  26. 8.5.1 BioFarma Company Information
  27. 8.5.2 BioFarma Business Overview
  28. 8.5.3 BioFarma Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 BioFarma Tuberculosis Vaccine Treatment Product Portfolio
  30. 8.5.5 BioFarma Recent Developments
  31. 8.6 GreenSignal Bio Pharma
  32. 8.6.1 GreenSignal Bio Pharma Company Information
  33. 8.6.2 GreenSignal Bio Pharma Business Overview
  34. 8.6.3 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Product Portfolio
  36. 8.6.5 GreenSignal Bio Pharma Recent Developments
  37. 8.7 China National Biotec
  38. 8.7.1 China National Biotec Company Information
  39. 8.7.2 China National Biotec Business Overview
  40. 8.7.3 China National Biotec Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 China National Biotec Tuberculosis Vaccine Treatment Product Portfolio
  42. 8.7.5 China National Biotec Recent Developments
  43. 8.8 Biomed Lublin
  44. 8.8.1 Biomed Lublin Company Information
  45. 8.8.2 Biomed Lublin Business Overview
  46. 8.8.3 Biomed Lublin Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Biomed Lublin Tuberculosis Vaccine Treatment Product Portfolio
  48. 8.8.5 Biomed Lublin Recent Developments
  49. 8.9 Taj Pharmaceuticals
  50. 8.9.1 Taj Pharmaceuticals Company Information
  51. 8.9.2 Taj Pharmaceuticals Business Overview
  52. 8.9.3 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Product Portfolio
  54. 8.9.5 Taj Pharmaceuticals Recent Developments
  55. 8.10 Ataulpho de Paiva
  56. 8.10.1 Ataulpho de Paiva Company Information
  57. 8.10.2 Ataulpho de Paiva Business Overview
  58. 8.10.3 Ataulpho de Paiva Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Ataulpho de Paiva Tuberculosis Vaccine Treatment Product Portfolio
  60. 8.10.5 Ataulpho de Paiva Recent Developments
  61. 8.11 IVAC
  62. 8.11.1 IVAC Company Information
  63. 8.11.2 IVAC Business Overview
  64. 8.11.3 IVAC Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 IVAC Tuberculosis Vaccine Treatment Product Portfolio
  66. 8.11.5 IVAC Recent Developments
  67. 8.12 Queen Saovabha Mem. Inst
  68. 8.12.1 Queen Saovabha Mem. Inst Company Information
  69. 8.12.2 Queen Saovabha Mem. Inst Business Overview
  70. 8.12.3 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Product Portfolio
  72. 8.12.5 Queen Saovabha Mem. Inst Recent Developments
  73. 8.13 Microgen
  74. 8.13.1 Microgen Company Information
  75. 8.13.2 Microgen Business Overview
  76. 8.13.3 Microgen Tuberculosis Vaccine Treatment Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Microgen Tuberculosis Vaccine Treatment Product Portfolio
  78. 8.13.5 Microgen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tuberculosis Vaccine Treatment Value Chain Analysis
  2. 9.1.1 Tuberculosis Vaccine Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tuberculosis Vaccine Treatment Sales Mode & Process
  6. 9.2 Tuberculosis Vaccine Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tuberculosis Vaccine Treatment Distributors
  9. 9.2.3 Tuberculosis Vaccine Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst